Suscripción por 2 €

Institutional-grade intelligence for professional investors

LIVE

•Real-time feeds•Global markets•24/7 coverage

Astellas Pharma Aktie News & Pressemeldungen

Noticias de Eulerpool Astellas Pharma

19/3/2024, 8:58:13

Bayer strebt Marktzulassung für Wechseljahres-Medikament an

1/8/2024, 10:11:58

Bayer plant Markteinführung von Elinzanetant in den USA

1/8/2024, 21:42:48

Harris' Grenzpolitik im Fokus der Republikaner: Differenzierte Bilanz und anhaltende Herausforderungen

15/10/2024, 11:53:02

Bayer zielt auf den europäischen Markt mit neuem Medikament: Hoffnungsträger gegen Hitzewallungen in der Menopause

20/10/2024, 21:28:29

Boeings neue Offerten und Branchenschlagzeilen: Ein Überblick

1

2

1

2

Astellas Pharma Noticias de Acciones

Astellas Pharma es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Astellas Pharma.

1 de julio ·
Yahoo
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
13 de junio ·
Yahoo
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
12 de junio ·
Yahoo
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
3 de junio ·
Yahoo
How leading oncology drugmakers set the stage for future advances
30 de mayo ·
Yahoo
Astellas and Evopoint sign ADC licensing deal
30 de mayo ·
Yahoo
Keros lays off nearly half its staff; Astellas buys into a China biotech’s ADC
30 de mayo ·
Yahoo
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
28 de mayo ·
Yahoo
Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers
27 de mayo ·
SeekingAlpha
Merck Proves Why It's Still A Top Pharma Pick
27 de mayo ·
Yahoo
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

1

2

1

2

Astellas Pharma Noticias de la acción

Astellas Pharma publica regularmente en la página web de la empresa noticias relevantes para los inversores.

Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Suscripción por 2 € / mes

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan